Reata Pharma (RETA) Tops Q1 EPS by 60c

Reata Pharma (NASDAQ: RETA) reported Q1 EPS of ($1.81), $0.60 better than the analyst estimate of ($2.41). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $191.43 thousand.

For earnings history and earnings-related data on Reata Pharma (RETA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Movano (MOVE) Misses Q2 EPS by 195c